More for AtCor
Thursday, 24 July, 2008
AtCor Medical [ASX: ACG] has reached new supply agreements for its SphygmoCor blood-pressure measurement systems.
The contracts are worth at least a combined $1.66 million. AtCor has secured $2.8 million worth of contracts in the past 60 days.
SphygmoCor is a blood pressure monitoring system that identifies the effects of reflected blood pressure in the central aortic pressure wave.
The company has sold over 1,400 SphygmoCors to medical institutions and research institutions conducting clinical trials, as the device can be used to measure the effects of medication on central blood pressure.
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
